

RCI MODEL RULES COMMITTEE
PETITION FOR NEW RULE OR CHANGE TO EXISTING RULE

Please submit this petition via email to rules@arci.com. Submissions received within 45 days of the next committee meeting will only be considered at that meeting at the discretion of the President or Chair of the Model Rules Committee. Printed petitions should be sent to:

Racing Commissioners
 International 1510 Newtown Pike,
 Suite 210
 Lexington, KY
 40511-2110

Your Contact Information:

Name:	Janet VanBebber
Organization:	American Quarter Horse Association
Address:	P.O. Box 200, Amarillo, TX 79168
Phone(s):	(806)378-4360 (713)446-4052
Fax #:	
E-mail Address:	jvanbeber@aqha.org

A. Brief Description of the Issue

1. AQHA would like for Albuterol to be added to Clenbuterol as a breed specific (Quarter Horse and Mixed Breed racing) prohibited drug.
2. Additionally, we would like for the ARCI to create a breed specific amendment to the penalty guidelines reclassifying Clenbuterol and Albuterol as a penalty class 3-A.

B. Discussion of the Issue and Problem (narrative provided)

Provide background on the issue to build context. Address the following:

- What specific problems or concerns are involved in this issue?*
- Who does the issue affect?*
- What existing model rules relate to this issue?*
- Provide relevant quantitative or statistical information if possible.*

C. Possible Solutions and Impact (narrative provided)

Provide possible recommendations to solve the problem. Include details on each proposed solution such as

- What solution does this proposal provide?*

- How will the solution fix the problem?*
- How will the change affect any entities or stakeholders?*
- How will you or your organization be affected by the proposed change?*
- What are the benefits of the proposed change?*
- What are the possible drawbacks of the proposed change?*
- Identify possible fiscal impact of the recommended change.*

D. Please identify any affected stakeholder groups that expressed support or opposition. (These stakeholders may include the racetracks, breed registries, owners, trainers, jockeys, veterinarians, or others.)


- For those stakeholder groups that have expressed an opinion, please list the points on which they agree or disagree, and the arguments they have expressed.*
- Are there any affected stakeholder groups that have not been consulted on this proposal?*
- Please submit any formal letters of support or opposition by stakeholder groups.*

E. Attach the model rule language you are proposing. Please show new language with underlined text. If you are proposing that current model rule language be eliminated, please strikeout the language to be deleted.

F. Do any racing jurisdictions currently have a version of this rule in effect? If yes, please attach copies of those rules.

G. Review the RCI Model Rules and identify any other Model Rules this change would affect and submit proposed amendments to those rules to comply with changes that would be made by this proposal.

FILING THIS REQUEST WITH RCI DOES NOT GUARANTEE YOUR PROPOSAL WILL BE CONSIDERED BY THE MODEL RULES COMMITTEE. IF YOU HAVE OPPOSITION FROM AN INTERESTED PARTY, YOU ARE STRONGLY ENCOURAGED TO TRY TO REACH CONSENSUS PRIOR TO FILING THIS FORM.

From: Janet VanBebber jvanbebbber@aqha.org 
Subject: Petition-for-a-Model-Rule
Date: November 21, 2018 at 12:20 PM
To: Ed Martin (emartin@arci.com) emartin@arci.com



Dear Ed,

Please submit the following narrative to support our petition for a model rule change provided in the attachment. We realize this request has more than one moving part, but per your request, we are consolidating the effort in one application.

Esteemed members of the Association of Racing Commissioners International,

The American Quarter Horse Association is respectfully submitting a proposal for your consideration. Our submission is twofold. First, we would like to address the topic of Albuterol.

As part of our ongoing effort to guard the welfare of the horse, and the industry as a whole, we must constantly endeavor to modify our rules and regulations to adequately address the current trends found in practice on the backsides of the racetracks. In this pursuit, it is imperative to review the model rule regarding Albuterol as it pertains to Quarter Horse and Mixed Breed racing. The medication Albuterol is only approved as an inhalant, but we have learned that horsemen are *injecting* the drug daily into the horses, and that like clenbuterol, it too has a repartitioning effect when administered in this off-label manner. In short, the medication is being abused nationwide as a performance enhancing drug. In the coming days, we will provide substantiation for the reported effects of the drug and offer insight to its abuse in human athletes, as well as statements from an Equine Practitioner about what is being done at racetracks. It is a fact that Albuterol is being widely abused, and may be related to the significant rise in distressed horses we are seeing after races. The American Quarter Horse Association maintains that we need to affect change as soon as possible in order to protect the wellbeing of our equine athletes.

In a second, but related, issue we are asking that a breed specific penalty be assigned to both Albuterol and Clenbuterol. When the ARCI adopted clenbuterol as prohibited in a breed specific manner, the penalty portion of the model rules was not updated accordingly. Consequently, a Quarter Horse trainer with a positive finding for clenbuterol could merely face a 3-B penalty, likened to a controlled therapeutic. We maintain that a positive finding for a **prohibited substance** should in fact have a correlating penalty, and ask that such be revised to a penalty 3-A.

We look forward to discussing this topic at the upcoming December meeting in Tucson. Additionally, we think there would be great value in tasking your Scientific Advisory Committee with investigating better ways to regulate the misuse and stacking of beta-agonist drugs including, but not limited to, Clenbuterol and Albuterol.

Thank you for considering these important topics. We appreciate the opportunity to collaborate in our constant endeavor to protect horse racing.

Most Sincerely,

JANET VANBEBBER

Janet vanBebber
Chief Racing Officer
American Quarter Horse Association



[Submit Spam](#) Petition-for-a-
Model-...le.docx

Delta Equine Center, LLC

P. O. Box 523

Vinton, LA 70668

Phone: 337-589-3078, Fax: 337-589-5835

*Dr. Larry Findley, Sr., Dr. Philip Appleton, Dr. Larry Findley, Jr.,
Dr. Troy Findley, Dr. Sara Bercier, Dr. Jaclyn Amador*

November 21, 2018

RE: Albuterol Usage

Association of Racing Commissioners International:

My name is Dr. Larry Findley, the principal owner of Delta Equine Center in Vinton, Louisiana. I have been asked by Janet VanBeeber, the Chief Racing Officer of the A.Q.H. A. to address the new emerging albuterol problem in Quarter racing horses.

We have recently, and progressively over the past few years, stopped the rampant use of the beta-adrenergic, clenbuterol. Clenbuterol was being used for its anabolic side effect to increase lean muscle mass in equine.

It has now come to our attention that they are substituting the drug Albuterol for this same purpose. Albuterol is used as a rescue inhaler for emergency bronchodilation in humans. It is also used for bronchodilation in horses when the animal is being treated with a nebulizer. Interestingly, it does not have an anabolic effect when inhaled, but does so when injected. Albuterol is possibly being compounded with other unknown drugs and being injected into the animals, rather than being inhaled.

I don't think God gave us these beautiful animals to be manipulated in this manner. In my opinion, the only way to stop albuterol misuse, is to make it

a prohibited substance for use in Quarter horses, in the same manner that was done with clenbuterol. This partitioning effect of albuterol, as with clenbuterol, has been proven scientifically.

Thank you, in advance, for your attention to the matter.

Sincerely,

A handwritten signature in black ink, appearing to read "Larry L. Findley, Sr.", with a long horizontal flourish extending to the right.

Larry L. Findley, Sr. DVM